Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ADMA BiologicsADMA -1.70%68 Revenue per Share is $2.14 as of Jun. 2026. GuruFocus rates ADMA with a GF Score™ of 68/100 and a GF Value™ of $18.35 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 767 Biotechnology companies, ADMA Biologics ranks better than 80.44% on this metric.
ADMA Biologics's revenue per share for the
three
months ended in Jun. 2026 was $0.54.
ADMA Biologics's revenue per share for the trailing twelve months (TTM) ended in Jun. 2026 was $2.14.
Warning Sign:
ADMA Biologics Inc revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue Per Share Growth Rate of ADMA Biologics was 11.10% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 38.80% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 36.70% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 9.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for ADMA Biologics's Revenue per Share or its related term are showing as below:
ADMA'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -21 Med: 16 Max: 44.6
Current: 38.8
During the past 13 years, ADMA Biologics's highest 3-Year average Revenue Per Share Growth Rate was 44.60% per year. The lowest was -21.00% per year. And the median was 16.00% per year.
ADMA's 3-Year Revenue Growth Rate is ranked better than 80.44% of 767
companies
in the Biotechnology industry
Industry Median: 3.3
vs ADMA: 38.80
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
ADMA Biologics Revenue per Share Related Terms
ADMA Biologics Revenue per Share Historical Data
* Premium members only.
The historical data trend for ADMA Biologics's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADMA vs VCEL, COAG, KLRA: Revenue per Share Comparison
For the Biotechnology subindustry, ADMA Biologics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADMA Biologics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADMA Biologics's PS Ratio distribution charts can be found below:
* The bar in red indicates where ADMA Biologics's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
ADMA Biologics's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.14
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADMA Biologics (ADMA) has a Revenue per Share of $2.14 as of Jun. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on ADMA Biologics and its competitors. According to the industry distribution chart, ADMA Biologics ranks #150 out of 767 companies in the Biotechnology industry, placing it in the top 19.6%.
Is ADMA Biologics' Revenue per Share too high?
ADMA Biologics' current Revenue per Share is $2.14. The Biotechnology industry median Revenue per Share is 3.30. ADMA Biologics' value of $2.14 is 35.2% below this industry median. Based on the distribution chart, ADMA Biologics ranks #150 out of 767 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ADMA Biologics has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' Revenue per Share compare to VCEL and COAG?
According to the Biotechnology industry distribution chart, ADMA Biologics ranks #150 out of 767 companies for Revenue per Share. This places ADMA Biologics in the top 20% of its industry — outperforming the majority of peers. The industry median Revenue per Share is 3.30. ADMA Biologics' value of $2.14 is 35.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Biotechnology company?
The median Revenue per Share among Biotechnology companies is 3.30, based on 767 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ADMA Biologics's current Revenue per Share of $2.14 is 35.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on ADMA Biologics and its competitors. For the Biotechnology industry, the median Revenue per Share is 3.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADMA Biologics's current Revenue per Share is $2.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $18.35, compared to a current price of $9.24 — trading 49.7% below its estimated fair value. The current Revenue per Share is $2.14 and 35.2% below the Biotechnology industry median of 3.30. ADMA Biologics' overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current Revenue per Share is $2.14 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADMA Biologics (ADMA) Overvalued in 2026?
Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued.
The current stock price of $9.24 is trading 49.7% below its estimated GF Value™ of $18.35.
GuruFocus considers ADMA Biologics to be Significantly Undervalued.
Key valuation signals for ADMA:
Revenue per Share: $2.14
GF Value™: $18.35 vs. price of $9.24 (49.7% below fair value)
Industry Position: 35.2% below the Biotechnology median (#150 of 767)
No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
68GF Score
Get the complete analysis for ADMA
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADMA has been successfully added to your 
